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This is an Experimental Statistics publication 
Experimental statistics are official statistics which are published in order to involve users and 
stakeholders in their development and as a means to build in quality at an early stage. It is 
important that users understand that limitations may apply to the interpretation of this data, 
further details of which are presented in this report. 
All official statistics should comply with the UK Statistics Authority’s Code of Practice which 
promotes the production and dissemination of official statistics that inform decision making. 
Once the evaluation is completed and an enhanced report is developed that meets the needs 
of users and stakeholders, the Experimental label will be removed. 
 
Find out more about the Code of Practice at:  
https://www.statisticsauthority.gov.uk/osr/code-of-practice/ 
 
Find out more about Experimental Statistics at:  
https://www.statisticsauthority.gov.uk/wp-content/uploads/2010/12/images-
assessmentanddesignationofexperimentalstatistic_tcm97-44327-1.pdf   
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The principal results of the 2015/16 Prevalence of Problem Drug Use Study were published 
on the Public Health Scotland (PHS) website as Official Statistics on Tuesday 5 March 2019. 
In line with previous studies Problem Drug Use (PDU) was defined as the problematic use of 
opioids (including illicit and prescribed methadone use) and/or the illicit use of 
benzodiazepines, and implies routine and prolonged use as opposed to recreational and 
occasional drug use. The final report can be found here: 
https://www.isdscotland.org/Health-Topics/Drugs-and-Alcohol-Misuse/Publications/ 
Although the study has been replicated a number of times in Scotland since 2000, no 
previous attempt has been made to systematically estimate the national prevalence of 
Problem Drug Use in a way that captures the extended problematic use of other substances 
such as cocaine (including crack cocaine), amphetamines (including amphetamine-type 
substances) and cannabis (including synthetic cannabinoids). 
In their 2019 report1, the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) noted that “Europe has witnessed some dramatic changes in the challenges the 
drugs area presents, including the appearance of more non-controlled substances. We have 
also seen significant changes in the drug market and drug use”. 
Notably there has not been a comparable definition or methodological approach adopted 
across the other regions of the United Kingdom. 
As part of the commission of the Study, the Scottish Government asked Public Health 
Scotland to consider, in addition to the current definition of PDU, the feasibility of estimating 
prevalence for a wider definition of drug types. This report describes the outcome of this work 
and also makes recommendations for future studies of the prevalence of Problem Drug Use 
based on the experience of this work.  




• Much of the problem drug using population is hidden, therefore drug prevalence figures 
can only ever be estimates, combining available data on observed cases with an estimate 
of the unknown population.   
• It is possible to generate estimates of prevalence for different definitions of Problem Drug 
Use using statistical techniques if sufficient source data on known cases can be 
accessed. 
• Drug Prevalence estimates must be interpreted with caution as there is much debate on 
the appropriate application of these methods amongst experts. 
• Three definitions have been considered. 
o Definition 1: Opioids (including illicit and prescribed methadone use) and/or the illicit 
use of benzodiazepines. 
o Definition 2: As definition 1, plus illicit use of cocaine and amphetamines / 
amphetamine type substances. 
o Definition 3: As definition 2, plus illicit use of cannabis / synthetic cannabinoids. 
• Estimated prevalence of problem drug users in 2015/16 increased from 1.62% under 
definition 1, to 1.91% under definition 2, and 2.51% under definition 3. 
• The percentage of problem drug users that are male was 71% under definition 1. This 
compares to 74% under definition2, and 77% under definition 3. 
• The percentage of problem drug users that are in the oldest age category (35-64) was 
64% under definition1. This compares to 58% under definition 2, 52% under definition 3. 
• The robustness of the estimates may decrease with the inclusion of previously excluded 
drug categories as defined previously for Scotland. 
• It is likely that the patterns of problem drug use in the population are changing as the 
demographic changes, and future studies will need to take account of this. 
• Ideally future studies should be based on routine, centrally held data and improvements to 
these will benefit these studies. 
• Potential future data sources should aim to capture representative samples of the target 
population, and avoid being heavily correlated. 
• Before undertaking a future approach additional external evidence and contextual data on 
the target population that could provide alternative estimates must be explored. 
• It is recommended that future studies are not only restricted to replicating the current 








Definition of Problem Drug Use 
The estimates reported here have been calculated separately for each Council Area using 
the same three data sources described in the 2015/16 main report. These were: 
• Clients registering with specialist drug treatment services 
• Drug-related hospital admissions  
• Criminal Justice Social Work (CJSW) reports 
In order to help Scottish Government (SG) and other stakeholders better understand the 
potential scale of wider Problem Drug Use distributions across Scotland, provision was made 
at the outset of the project to collect data for a wider range of drug-types whilst maintaining 
capabilities to replicate the previous methods as closely as possible. 
Prior to the data collection phase of the study, Public Health Scotland consulted with the 
Advisory Group set up for the study and the Harms subgroup of the Partnership for Action on 
Drugs in Scotland (PADS) for advice. Based on this and in discussion with the SG, two new 
definitions were agreed to be explored in addition to the existing definition of PDU. 
Where reference is made to Definition 1 in this report, this relates to the current published 
definition and selection criteria which includes Opioids and Benzodiazepines only. 
Collecting additional data on cocaine (including crack cocaine), amphetamines (including 
amphetamine-type substances) and cannabis (including synthetic cannabinoids), created 
new opportunities to expand the breadth of composite PDU definitions. Two further PDU 
definitions were therefore selected for analysis. The constituents of each definition are 
described below: 
 Drug Category Definition 1 Definition 2 Definition 3 
Opioids    
Benzodiazepines    
Cocaine (including crack cocaine)    
Amphetamines and amphetamine-type substances (ATS)    
Cannabis/Synthetic Cannabinoids    
 
A full description of the inclusion criteria (substances or diagnostic codes) adopted for case 
selection within each drug category is provided in Appendix 1. 
 
Statistical Methods 
The statistical methods used to estimate the prevalence based on the wider definitions were 
the same as for the original report, namely capture-recapture using log-linear modelling. This 
allowed direct comparison of the effect of the changing definitions of problem drug use on 
estimates.  
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A fundamental aspect of this statistical technique is the ultimate selection of a single best-
fitting model (or composite set of best-fitting stratified models) for each council area. The 
original report describes the selection fully in terms of ten hierarchical steps. This iterative 
process begins with an initial construct of 63 statistical models, made up of 7 model 
configurations and 9 strata, produced separately for each council area. This process was 
replicated for the two new definitions. Deviation from the criteria used to select the best-fitting 
model in the original report was necessary on occasion to derive valid estimates from log-
linear models. These are described in more detail in Appendix 2. 
Many of the council area estimates were formed without the need to stratify the models. As a 
result, further breakdowns of the estimates by age and sex could not be directly computed. In 
order to provide estimates according to age and sex, fully stratified models were created at 
an aggregate regional level. Age/Sex-specific weightings were extracted from each of the 
three stratified sets of regional models, and these were used to distribute the previously 
calculated council area estimates according to age and sex. This method is described fully in 
the main report.  
Having a measure of uncertainty in each of the modelled estimates is vital and is reflected 
through the use of 95% confidence intervals. The method used to construct confidence 
intervals in this and previous iterations of drug prevalence studies for Scotland, is known as a 
bootstrap method. 
Bootstrapping is the practice of estimating prevalence by repeatedly re-sampling the same 
data and computing the estimate of the unknown population for each sample. Cases are 
selected randomly, with replacement, from the original sample to create each new sample. 
Typically, each new sample has the same cases as the original sample, but some cases may 
be selected multiple times and others not at all. After a suitably large number of bootstrap 
samples are made, the empirical distribution of the estimate is observed and the interval 
between two percentiles is taken as the confidence interval.   
This method is described fully in the main report.  
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Results and Commentary 
This section presents both observed populations, based on actual number of individuals with 
problem drug use ascertained across the data sources, and the estimated populations, which 
in addition include predicted numbers of problem drug users not captured on any of the data 
sources. 
Population rates are based on 2015 published population estimates for Scotland. 
 
Observed Number of Individuals with Problem Drug Use  
Table 1 - Known Population Gender Distributions for Scotland Overall 
 Female (%) Male (%) Total 
Definition 1  10,520 31.5% 22,891 68.5% 33,411 
Definition 2 10,937 30.6% 24,863 69.4% 35,800 
Definition 3  11,703 29.1% 28,539 70.9% 40,242 
 
Table 2 - Known Population Demographic Age Distributions for Scotland Overall 
 15 - 24 (%) 25 - 34 (%) 35 - 64 (%) Total 
Definition 1  1,827 5.5% 9,278 27.8% 22,306 66.8% 33,411 
Definition 2 2,703 7.6% 10,066 28.1% 23,031 64.3% 35,800 
Definition 3  4,369 10.9% 11,398 28.3% 24,475 60.8% 40,242 
 
Table 3 - Known Population Data Source Distributions for Scotland Overall* 
 Services (%) SMR (%) CJSW (%) Total 
Definition 1  30,046 89.9% 4,052 12.1% 4,164 12.5% 33,411 
Definition 2 31,134 87.0% 4,891 13.7% 4,864 13.6% 35,800 
Definition 3  33,217 82.5% 5,678 14.1% 6,869 17.1% 40,242 
* Note data sources do not sum to total due to individuals appearing on more than one source. 
Table 1 shows that the number of individuals with problem drug use as identified across the 
data sources increased from 33,411 under definition 1 to 35,800 under definition 2.  This 
represents an increase of 2,389 or 7% by including cocaine/crack and amphetamines/ATS.  
There was a further increase of 4,424 or 12% under Definition 3 which also included 
Cannabis.  
Table 1 also shows that 68.5% of the known population according to definition 1 were male. 
The impact of adding cocaine (including crack cocaine) and amphetamines (including 
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amphetamine-type substances) into definition 2 resulted in a slight increase in the proportion 
that were male (69.4%), and this increased further when cannabis (including synthetic 
cannabinoids) were included in definition 3 (70.9%). 
Table 2 shows that 5.5% of the known population according to definition 1 were in the 
youngest age category (15-24). This increased to 7.6% when cocaine (including crack 
cocaine) and amphetamines (including amphetamine-type substances) were incorporated 
into definition 2, and rose further with the inclusion of cannabis (including synthetic 
cannabinoids) in definition 3 (10.9%). 
Table 3 shows that under definition 1, the vast majority of individual problem drug users 
appeared, and only appeared, in the treatment services data.  Very few appeared in the 
hospital admission data (12%) and criminal justice data (12%).  However, the additional 
problem drug users identified under definition 2 were more likely to appear in both the 
hospital admission data (35%) and criminal justice data (29%). The further problem drug 
users of cannabis identified under definition 3 were more likely to appear in the criminal 
justice data (45%) rather than the hospital admission data (17%). 
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Estimated Number of Individuals with Problem Drug Use  
Table 4: Estimated prevalence (numbers and rates) of problem drug use for Scotland 
 Number Rates (%) 
  95% Conf Interval  95% Conf Interval 
  Low High  Low High 
Definition 1  57,272 55,788 58,857 1.62% 1.58% 1.66% 
Definition 2 67,522 65,833 69,600 1.91% 1.86% 1.97% 
Definition 3  89,000 85,726 94,029 2.51% 2.42% 2.66% 
 
Following statistical modelling at council area level, Table 4 presents prevalence estimates 
for each definition in terms of the number of cases and associated rate (%) per head of 
population for Scotland as a whole. Estimated prevalence of problem drug users increased 
markedly from 1.62% under definition 1, to 1.91% under definition 2, and 2.51% under 
definition 3. 
 
Figure 1: Estimated prevalence rates (%) of problem drug use for Scotland 
 
Figure 1 shows the estimated prevalence rates per head of population with associated 
confidence intervals for each of the definitions. Confidence intervals quantify the extent of 
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Table 5: Estimated prevalence of problem drug use by age and gender for Scotland 
 Definition 1 Definition 2 Definition 3 
 15-24 25-34 35-64 15-24 25-34 35-64 15-24 25-34 35-64 
Males 4,800 9,700 26,200 9,600 11,700 28,500 13,700 20,500 34,600 
Females 1,100 5,200 10,300 1,400 5,500 10,700 2,400 6,000 11,800 
Total 5,900 14,900 36,500 11,000 17,200 39,200 16,100 26,500 46,400 
 
Figure 2: Gender (%) distribution of the estimated prevalence of problem drug use for 
Scotland 
 
Figure 2 shows that after the introduction of specific new drug categories, the resulting 
models simulate a more male dominated profile of problem drug use in Scotland. The 
percentage of problem drug users that are male was 71% when PDU was defined in terms of 
the problematic use of opioids and benzodiazepines only. However, this increased to 74% 
with the addition of cocaine (including crack cocaine) and amphetamines (including 
amphetamine-type substances), and to 77% when cannabis (including synthetic 
cannabinoids) was ultimately included in definition 3. Table 5 shows that the percentage of 
problem drug users in the youngest age category that are male was 81% for definition 1 and 































Public Health Scotland 
 
12 




Table 5 and Figure 3 show the effect of age after the introduction of the new drug categories, 
and how the chosen models in these circumstances simulate the emergence of a younger 
profile of problem drug use in Scotland. The percentage of problem drug users that are in the 
oldest age category (35-64) was 64% when PDU was defined in terms of the problematic use 
of opioids and benzodiazepines only. However, this decreased to 58% with the addition of 
cocaine (including crack cocaine) and amphetamines (including amphetamine-type 
substances), and to 52% when cannabis (including synthetic cannabinoids) was ultimately 
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Figure 4: Known and Estimated Populations as % of the Scottish Population (aged 15-
64) 
 
Figure 4 presents estimated prevalence rates compared against the known population counts 
similarly expressed as rates per head of population. The chart demonstrates that the 
incremental increase in the known population level, as new substances are added to the 
definitions, results in a disproportionately larger increase in the levels of estimated 
prevalence. The inclusion of cocaine (including crack cocaine), and amphetamines (including 
amphetamine-type substances) resulted in an increase in the known population of 7% but an 
increase in the estimated population of 18%.  The inclusion of cannabis (including synthetic 
cannabinoids) into definition 3 resulted in a further increase in the known population of 12% 
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This extended work has shown that it is possible to generate estimates of prevalence for 
wider definitions of Problem Drug Use using log-linear capture/recapture techniques. 
However, the results suggest that the robustness of the estimates may decrease with the 
inclusion of previously excluded drug categories. 
Ultimately the estimates are a function of the extent of overlaps observed for each individual 
across data sources, and the pattern of overlaps changes markedly with the introduction of 
the new categories. The methods adopted in Scotland require us to accept that certain 
underlying modelling assumptions hold. This includes the assumption that the models used 
to estimate are based on a single homogeneous population with the relationships between 
individuals appearing in different data sources adequately captured by the interactions. This 
will not be met if there is ‘heterogeneity’ within the population, leading to specific groups of 
individuals having different probabilities of appearing in a particular source. 
As we have added cocaine (including crack cocaine) and amphetamines (including 
amphetamine-type substances) to Definition 1 in order to form Definition 2 and further added 
cannabis (including synthetic cannabinoids) to form Definition 3, we can see in the known 
populations a probable exacerbation of bias against this assumption, and this is likely having 
a significant influence on the observed need to relax model acceptance criteria. 
In the published results for Definition 1 we encountered that younger male problem drug 
users are more likely to appear in criminal justice social work reports than through drug 
treatment or hospital admission records. So an element of bias would already exist. The 
results show that this pattern continues with the expansion to definitions 2 and 3, where 
younger males are disproportionately appearing in criminal justice social work reports. 
Optimal compliance against the above assumptions is entirely subject to the quality and 
completeness of the source data. The robustness of estimates is subject to the inherent 
representativeness of the sources, but this is complicated by potential inconsistencies in the 
data gathered across each of Scotland’s 32 council areas. The ascertainment of cases for 
the new drug categories, from drug treatment services, highlighted some further potential 
bias in the data. In order to focus on problematic users, criteria had been set such that these 
observations should be recorded on the basis of main drug. The inclusion of cocaine and 
cannabis in the returns provided by local services showed larger regional variations than 
existed when Opioids and Benzodiazepines were considered in isolation.  
The project advisory group, which is made up of long-standing leading experts in this field 
cautioned at the outset that the methods would not hold up well against certain underlying 
assumptions, and this appears to come through in the data collected. 
The uncertainty in the estimates is reflected through confidence intervals however these are 
specific to the final chosen models and assume all statistical assumptions for these models 
hold. There can be a tendency for users to focus on the point estimate and assume this as an 
absolute comparator, rather than consider the error-bounds and look for overlaps. We 
present further discussion in this regard by considering some individual council area 
estimates in Appendix 2. 
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Methodological Considerations for Future Studies 
 
Other UK Countries 
The latest available prevalence estimates for Wales cover the period 2015-16, and were 
published by Public Health Wales2 in November 2018. Their definition includes “injecting drug 
use or long-duration/regular use of opioids, cocaine and/or amphetamines (including 
amphetamine type substances)”. 
The authors of this report were also members of the Advisory Group to the Scottish study. 
The estimates for Wales are not stratified by age and sex. Their source datasets include 
records of police arrests, engagement with drug intervention programmes managed by 
probation services, assessments by substance misuse treatment, hospital admissions and 
accessing statutory, voluntary and pharmacy needle and syringe programmes (NSPs). 
Previous estimates for Wales used only three data sets (police arrests, probation assessment 
and treatment referrals) and as such the report cautions that they are not comparable with 
latest estimates as a result. Prevalence statistics for Wales are now derived from applying 
Bayesian techniques to the data, although they do describe the approach preferred in 
Scotland as the “traditional statistical method” “still used by many researchers”. Updated 
figures for 2016-17 and 2017-18 are not currently available but work is ongoing within Public 
Health Wales to progress this. This is due to concerns around the variability in the known 
datasets and how this reconciles against the modelling techniques. 
Prevalence statistics for England are produced on behalf of Public Health England by 
Liverpool John Moores University. The latest available estimates for England cover the 
period 2016-17, and were published3 in March 2019. Their definition includes the use of 
opiates and/or the use of crack cocaine. They emphasise that the case definition focuses on 
the ‘use’ of opiates and/or crack cocaine rather than the ‘misuse’ of these drugs or addiction 
to either drug. Furthermore, the case definition does not include the use of cocaine in a 
powder form or the use of any other substances such as amphetamines, ecstasy or 
cannabis.  
The lead author of the report was also a member of the Advisory Group to the Scottish study. 
Unlike Scotland and Wales, England also provides separate estimates for their constituent 
drug categories, such as the prevalence of opiate use, and the prevalence of crack cocaine 
use. Like Scotland, their estimates are stratified by the same three age categories. Four 
sources of data underpin the estimates, these are routinely available and include, drug 
treatment, probation, police and prison data. The methods used to estimate the size of the 
'hidden' opiate and/or crack cocaine using population are similar to those used in the current 
study. Indeed, the methodology used in Scotland was originally set up by the English team 
and has not changed in recent studies. The current English method however supplements 
the capture-recapture log-linear modelling approach with the multiple indicator method for 
areas where a valid estimate could not be derived. 




The majority of problem drug users are hidden. In order to estimate the hidden population 
good quality representative data on known problem drug users has to be sourced for all 
Council Areas in Scotland. In previous studies four sources (Drug Treatment, Hospital 
Admissions, Criminal Justice Social Work and Police) provided the most readily accessible 
data. 
However much of this data is not routinely collected nationally, and a significant aspect of the 
work has been the coordination and management of new collections. Only hospital admission 
data are accessible from a national data repository. In England and Wales, representative 
data sources are more readily available to the lead researchers. The latest study for Scotland 
focussed at the outset on securing new data through Alcohol and Drug Partnerships (for 
those receiving specialist drug treatment), Social Work Services (for those subject to Criminal 
Justice Social Work Reports), and the Police (for those arrested or detained in relation to the 
Misuse of Drugs Act). 
The most significant and unexpected challenge, was in accepting that data from Police 
Scotland could not be secured for this study. Despite their best efforts, complete data for all 
regions could not be gathered in a way that would be compliant with the requirements for the 
study. This was due to changes in the data system architecture introduced after the launch of 
Police Scotland and the last Drug Prevalence study for 2012/13. These system changes are 
designed to serve the specific nature of a new drug reporting framework for the Police, and 
could not be reconciled with the very specific prevalence data requirements. 
In working towards a decision on whether to proceed without data from Police Scotland, 
analysis demonstrated that the scale of point estimates remained, for the majority of areas, 
reasonably stable compared to the corresponding previous estimates for 2012/13. Clearly 
there were some significant variations in particular areas, but overall the Scottish estimate 
was similar to the level previously obtained. We speculated that the high overlaps inherent 
between criminal justice social work and police arrests data could provide some degree of 
offset, and their high interdependency might actually call into question the logic of including 
both as independent sources. 
Also the fact that we were proving successful in securing good quality new data directly from 
alcohol and drug partnerships and from criminal justice social work departments, satisfied us 
to proceed without Police Scotland data. Police Scotland advise that in future there are 
systems that could potentially be ‘mined’ for information of the nature required, but in the 
absence of a technological solution to extract the data, this would need to be done manually 
at significant cost. 
Although the other data collections were providing fruitful returns, the process proved to be 
extremely time consuming and placed a significant burden on each local authority to find 
resource to administer the process across both of their ADP and CJSW arms. For the first 
time, the Scottish study had gone through and received approval from the Public Benefit and 
Privacy Panel for Health and Social Care. The application and approval process took six 
months and made further requirements on how the data should be collected and protected. 
Detailed data sharing agreements had to be negotiated with each individual area under new 
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legislative conditions introduced by the General Data Protection Regulations (GDPR) which 
came into force coincidentally during the negotiations (in May 2018), and had to be 
reconciled for compliance against existing study protocols. 
The timeline from initial contact with service leads through to the conclusion of final data was 
18 months. This was against an initial provision that was made for data to be collected in half 
that time. Despite the delays the study secured a comprehensive dataset for those in 
treatment that was validated by the service. The ability to link and augment direct drug 
treatment submissions with data already routinely collected through the Scottish Drug Misuse 
Database proved particularly useful and brought about an apparent sizeable increase in 
known cases compared to levels that had been achieved in previous studies. 
If the need to estimate overall prevalence remains, a review of existing routine data may 
provide a more efficient future means of securing baseline data for estimation purposes. This 
would have to be carried out in conjunction with a review of methods (see section on 
Statistical Methods). 
Public Health Scotland recommend a review of the potential utility of the following datasets 
be carried out in advance of future prevalence work:   
• SDMD / DAISY 
• Probation and prison service data 
• Needle exchange data (NEO) 
• Prescribing data (for ORT)  
• GP data (SPIRE) 
During work on the study, the Scottish Public Health Drug Linkage Programme has been 
under development in Public Health Scotland. This may go some way to address issues of 
access to linked drug-related data sources for prevalence purposes. This data linkage project 
includes drug treatment, prescribing and hospital admission records, so a large proportion of 
the population will be included. 
This resource, in itself, will not circumvent the need to formulate an estimation technique, but 
could provide a platform for ready-access to linked data without the need to engage partners 
in bespoke single-use data collections. We envisage that it will be useful for looking at 
outcomes e.g. hospitalisation rates, death rates, and opens up opportunities for new and 
alternative methods to be brought online, e.g. synthesis or multiplication methods. Other 
benefits of having an established linked platform, will be the opportunity to refresh the 
estimates more regularly than the existing three-yearly cycle. 
  




The current study aimed to keep the statistical methodology the same as in previous studies 
to allow for comparisons of trends in estimated prevalence and to investigate the effect on 
estimates of adding additional data for a wider set of problem drug types.   
It is clear from literature there is no single universally accepted method to estimate a hidden 
population of problem drug users from available data sources and a number of approaches 
have been, and continue to be, proposed. Estimating a hidden population using data on 
individuals recorded in routine data sources is implicitly going to result in a degree of 
uncertainty, particularly when the hidden population can be at least as large as the recorded 
population as predicted here. Therefore, any statistical estimate requires assumptions to be 
made and the degree to which these assumptions hold can be difficult to validate. This in turn 
affects the range of uncertainty to be applied around a particular estimate.    
There are a number of approaches that have been proposed over the years by bodies such 
as the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and capture-
recapture methods such as used in this study, also referred to as mark-recapture methods, 
are commonly used. Hay and Richardson (2016)4 give a good summary of the development 
of these methods in this area, such as Bayesian analysis, and also address some of the 
criticisms of the approach. They do however recognise that “there is a general feeling that the 
quality of the data that are available in these applications is not adequate to support more 
than basic analyses”. 
Using capture-recapture there are options available and assumptions that can be made to 
produce a final, chosen estimate of the hidden population, including:   
• which and how many data sources to use; 
• choice of model parameters and interactions;  
• whether to stratify or include covariates to account for population heterogeneity;  
• Bayesian or maximum likelihood methods of model fitting;  
• choice of prior distributions for Bayesian methods; 
• choice of model selection criteria for maximum likelihood. 
It was evident in this study the considerable range of estimates of the hidden population that 
are possible within a single local authority area, depending on these choices and their 
dependence on some pre-determined statistical criteria for selection of a ‘final’ estimate. 
Even confidence intervals that have been provided in this study are unlikely to capture the full 
range of uncertainty in estimates since they are conditional on the final selected model 
always being the true representation of reality.   
Experts in these methods, including members of the Advisory Group, guard against the 
‘naive’ and routine application of capture-recapture methods and stress the importance of the 
quality of the underlying data and an understanding of the pathways individual users may 
experience that are reflected across the data sources. Jones et al (2015)5 in particular 
highlight that referrals between the data sources will impact on assumptions used in the 
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models and propose streamlining the data used in modelling by identifying and including only 
new incident cases appearing in data sources during the period of interest. 
Given the uncertainty in the range of possible estimates using any single method, 
researchers in this field have proposed using more than one method and source of evidence 
to triangulate estimates and increase certainty in the likely range of estimates6. For example, 
the multiplier method, using drug-related death rates, or the multivariate indicator method as 
used in English estimates, could provide alternative approaches to complement capture-
recapture based estimates. 
Bayesian methods are a more formal way to include prior information and other relevant 
external data to take account of uncertainty in the model-fitting process for capture-recapture 
methods7,8. Where valid external data or research results exist that could inform prevalence 
rates, these could be articulated in prior estimates which are fed into the statistical modelling 
and guide the choices of the resulting, posterior, estimates. This results in a weighted 
average across the various estimates derived from competing models which quantifies a 
number of sources of uncertainty but in itself does not guarantee a valid estimate. 
Bayesian methods can also be used when relevant prior information reflecting different 
aspects of the hidden population is available from a number of sources of varying reliability 
such as routine data sources and published research, or even expert opinion. These can be 
brought together and modelled within a multiple parameter evidence synthesis framework 
model9. Evaluating the Population Impact of HCV DAA Treatment as Prevention for PWID 
(EPIToPe) is a current research programme into treatment for hepatitis C that will employ 
such methods to estimate the prevalence of injecting drug users. The Scottish Public Health 
Drug Linkage Programme proposal to link a range of health service data such as 
hospitalisations, prescriptions and deaths to data on individuals receiving drug treatment 
services in Scotland will provide a ready source of information on outcomes and service use 
for a large cohort of known problem drug users. This will be instrumental in developing these 
methods as a possible alternative to the current capture-recapture method. 
When no relevant and reliable external data exist, however, Bayesian methods will not 
appreciably differ from maximum likelihood in that estimates will be driven by the study data.  
In the current study no prior external data was readily available a priori to inform estimation of 
PDU prevalence (other than previous estimates based on similar methodology). Previously 
however, prior information on drug related death rates from cohort studies has been used to 
inform estimates of injecting drug use specifically10. This research used, in addition to the 
three sources used in the current study, data on hepatitus C diagnoses likely due to injecting 
use. Therefore, future studies would benefit from systematically reviewing a priori evidence 
available to inform estimates of PDU for a given definition of drug types and its robustness. 
  




The current study has been able to produce credible estimates for prevalence of PDU, based 
on the existing definition, despite the loss of police arrest data. However, this has been at 
considerable expense and longer than expected timescales to ensure good quality new data 
was available on individuals using drug treatment services and/or appearing on social work 
reports ahead of sentencing within the criminal justice system. 
Data on a wider set of problem drugs, including cocaine, amphetamines and cannabis has 
also been collected for the first time. This data is highly beneficial in helping understand the 
emerging patterns of problem drug use in the population. However, population prevalence 
estimates for these additional drug types are less reliable using the same methods and data 
sources. 
It is likely that the patterns of problem drug use in the population are changing as the 
demographic changes and this means greater heterogeneity within the population of drug 
users. Future studies of prevalence will need to take account of these changes when 
deciding on definitions of PDU, potential data sources, types of data collected and statistical 
methods used to estimate the hidden population. Since these four aspects are inter-
dependent, this precludes there being a fixed methodology for estimating PDU going forward. 
Future studies would benefit from an initial phase focussing on definitions of PDU and 
potential data sources available that capture these users. Potential data sources should aim 
to capture representative samples of the target population, and avoid being heavily correlated 
by covering different aspects of a problem drug use ‘pathway’, such as different treatment 
regimes, criminal justice system, outcomes and harms.  Understanding the links and referral 
patterns between data sources will be of particular importance. 
Ideally future studies would be based on routine, centrally held data and improvements to 
these will benefit these studies by reducing data collection costs. However, some new data 
collection might still be necessary to ensure full coverage of drug treatment services and to 
include data from criminal justice sources to complement health service data. The information 
governance requirements for any new data collection, and its effect on timelines, should be 
considered carefully given the experience of the current study following the implementation of 
GDPR in particular. Further work is recommended to explore the feasibility of more readily 
accessing data on potential drug users within Police Scotland records. This could take 
advantage of developing statistical methods for analysing text-based and unstructured data. 
This initial phase could also review available external evidence and contextual data on the 
target population that could provide alternative estimates, e.g. using the multiplier method, or 
to form prior information to feed into a Bayesian approach such as an evidence synthesis 
model. This external evidence could be gleaned from reviews of published research, grey 
literature and other relevant analyses. The proposed Scottish Public Health Drug Linkage 
Programme would be a particular source of additional contextual data for a large proportion 
of the likely target population. 
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The outcome of this initial phase would inform the statistical methodology to be used and the 
format of data required to be collected from new sources. Therefore, it is recommended that 
future studies are not only restricted to replicating the current methodology and data sources.   
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Amphetamine Amphetamines are central nervous system stimulants prescribed 
in the treatment of various conditions. Amphetamine-type 
stimulants (ATS) refer to a group of drugs whose principal 
members include amphetamine and methamphetamine. A range 
of other substances also fall into this group, such as 
methcathinone, fenetylline, ephedrine, pseudoephedrine, 
methylphenidate and MDMA or ‘Ecstasy’ – an amphetamine-type 
derivative with hallucinogenic properties. 
 
Benzodiazepine The most commonly prescribed minor tranquilisers, known as 
anxiolytics (for daytime anxiety relief) and hypnotics (to promote 
sleep).  Includes diazepam (Valium), lorazepam, librium, 
nitrazepam, temazepam. 
 
Cannabis Cannabis is a generic term used to denote the several 
psychoactive preparations of the plant Cannabis sativa. The major 
psychoactive constituent in cannabis is ∆-9 tetrahydrocannabinol 
(THC). Compounds which are designed to act like THC are 
referred to as cannabinoids. 
 
Capture-recapture This form of analysis uses data sources which in some way 
identify individuals with problem drug use to identify the overlap 
between the data sources.  Further analysis can then be used to 
estimate the hidden (unknown) population who appear in none of 
the data sources, which, combined with the known population, 
generates a prevalence estimate. 
 
Cocaine Also known as coke or crack, cocaine is a strong stimulant most 
frequently used as a recreational drug. 
 
Confidence interval Provides an estimated range of values within which the true value 
is likely to lie.  The width of the confidence interval gives an 
indication of the reliability of the value (i.e. the smaller the range 
the more reliable the value). 
 
Hidden population The individuals with problem drug misuse who are not captured in 
any of the datasets used for the study. 
 
Known population The individuals identified with problem drug use in the datasets 
used for the study. 
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Opioid A drug containing opium or its derivatives, used in medicine for 
inducing sleep and relieving pain.  Includes heroin (diamorphine), 
morphine, methadone, opium, codeine, pethidine, dihydrocodeine 
(DF118). 
 
Prevalence In epidemiology, the prevalence of a health-related state (typically 
disease, but also other things like drug use) in a statistical 
population is defined as the total number of cases of the risk 
factor in the population at a given time. It is used as an estimate 
of how common a disease is within a population over a certain 
period of time.  The prevalence rate is the number of individuals 
shown as a proportion of the overall population. 
 
Problem drug use The problematic use of opioids (including illicit and prescribed 
methadone use) and/or the illicit use of benzodiazepines and 
implies routine and prolonged use as opposed to recreational and 
occasional drug use.   
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Further Information can be found on the PHS website. 
For more information on Drug Prevalence see the Prevalence of Problem Drug Use section 
of our website. For related topics, please see the Drugs Misuse pages. 
 
  




Appendix 1 – Drug Category Inclusion Criteria 
 
Specialist Drug Treatment and Criminal Justice Social Work Reports 
Drug Category Inclusion Criteria 
Opioid/Opioid Replacement 
Therapy (ORT)  
 
 
Current users of Heroin or those on Opioid Replacement 
Therapies (ORTs) included within this category. 
 
The list of drugs that describe ORTs are as follows. Both illicit and 
prescribed use of ORTs should be considered problematic:  
   
Methadone 
Buprenorphine (Subutex) 
Buprenorphine & naloxone (Suboxone) 
Lofexidine (Britlofex) 
 
The following list of drugs also fall within the Opioid category and 
many of them are prescription drugs. Illicit use of these drugs should 
always be considered problematic. The prescribed use of these 
drugs is only to be considered problematic if they are being 






























AH-7921 (Doxylam)   
Benzodiazepine use 
 
Current problematic use of Benzodiazepines included within this 
category. 
 
The following list of drugs fall within the Benzodiazepine category 
and many of them are prescription drugs. Illicit use of these drugs 
should always be considered problematic. The prescribed use of 
these drugs is only to be considered problematic if they are being 




























Slang terms: Blues, downers, roofies 
Cocaine use Current problematic use of Cocaine or Crack Cocaine should be 
included within this category. 
 
Note: The study aims to capture routine and prolonged use, 
therefore recorded only if cocaine or crack cocaine is the ‘main’ drug 
on specialist drug treatment records. The advice in relation to data 
sourced from CJSW records was to record if occasional or 
recreational use is implied in the report, but to err on side of 
recording if it was not clear.  







Current problematic use of Amphetamines or Amphetamine-Type 
Substances should be included within this category. 
 
The following list of drugs fall within the Amphetamine/ 
Amphetamine-Type Substance category. The illicit use of these 
drugs should always be considered problematic. The prescribed use 
of these drugs is only to be considered problematic if they are being 
prescribed in the course of drug treatment (e.g. as a treatment for 
addiction). 
 
Note: The study aims to capture routine and prolonged use, 
therefore record only if the Amphetamine or 
Amphetamine-Type Substance is the ‘main’ drug.  
 
Amphetamine (Speed) 
Amphetamine Sulphate (Benzedrine, or ‘Bennies’) 
Methamphetamine (Methedrine) 
Crystal Methamphetamine (Crystal Meth) 











































Current problematic use of Cannabis or Synthetic Cannabinoids 
included within this category. 
 
Note: The study aims to capture routine and prolonged use, 
therefore recorded only if Cannabis or Synthetic Cannabinoid is the 
‘main’ drug on specialist drug treatment records. The advice in 
relation to data sourced from CJSW records was to record if 
occasional or recreational use is implied in the report, but to err on 
side of recording if it was not clear.  
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Drug-Related Hospital Admissions (SMR01 / SMR04) 
Information was extracted from centrally held data within NHS National Services Scotland 
(NSS). The data, which was initially sourced from NHS hospital administration systems 
across Scotland, relates to inpatient and day case admissions to general acute (SMR01) and 
mental health specialties (SMR04).  
The recording of diagnoses on SMR01 and SMR04 comprise a main condition and, 
optionally, up to five further conditions. All conditions on data submissions for hospital 
discharges from 1st April 1996 have been coded according to the 10th revision of the 
International Classification of Diseases and Injuries (ICD-10).  
 
The following selection criteria have been applied to each of the study drug categories: 
Opioids 
F11 - Mental and behavioural disorders due to use of opioids 
T40.0 - Poisoning by narcotics and psychodysleptics (Opium) 
T40.1 - Poisoning by narcotics and psychodysleptics (Heroin) 
T40.3 - Poisoning by narcotics and psychodysleptics (Methadone) 
Benzodiazepines 
F13 - Mental and behavioural disorders due to use of sedatives or hypnotics 
Cocaine/Crack Cocaine  
F14 - Mental and behavioural disorders due to use of cocaine 
T40.5 - Poisoning by narcotics and psychodysleptics (Cocaine) 
Amphetamines/Amphetamine-Type Substances  
F15 - Mental and behavioural disorders due to use of other stimulants, including caffeine 
T43.6 - Poisoning by psychotropic drugs, not elsewhere classified (Psychostimulants with 
abuse potential) 
Cannabis  
F15 - Mental and behavioural disorders due to due to use of cannabinoids 
T40.7 - Poisoning by narcotics and psychodysleptics (Cannabis) 
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Appendix 2 – Local Area Estimates 
The national estimates presented in this report are a function of individual estimates 
produced for each of Scotland’s council areas. The inclusion of cocaine (including crack 
cocaine) and amphetamines (including amphetamine-type substances) in definition 2 
resulted in three council areas (Aberdeenshire, East Ayrshire, Falkirk) where no models 
could be fitted using the established criteria (hierarchical steps). The further inclusion of 
cannabis (including synthetic cannabinoids) in definition 3 resulted in five areas where no 
models could be fitted using the established criteria (City of Edinburgh, East Ayrshire, East 
Dunbartonshire, Falkirk, Na h-Eileanan Siar). In order to generate estimates for these areas, 
it was necessary to progressively relax the criteria until a best-fitting model or composite set 
of stratified models could be found for each council area. We also encountered that variation 
in estimates across competing models increased with the widening criteria. 
The uncertainty in the estimates at Scotland level have been reflected through confidence 
intervals, at council area level these are specific to the final chosen models and assume all 
statistical assumptions for these models hold. There can be a tendency for users to focus on 
the point estimate and assume this as an absolute comparator, rather than consider the 
error-bounds and look for overlaps. 
The estimated prevalence counts for each council area that have been combined to form the 
national estimates are presented on the following page. 
The wider results for certain areas demonstrate some challenges to the meaningful 
interpretation of estimates calculated across a spectrum of definitions. For instance, by 
looking solely at the point estimate for East Dunbartonshire the results suggest that 
prevalence increased from 706 to 862 with the addition of cocaine (including crack cocaine), 
and amphetamines (including amphetamine-type substances). However, when cannabis 
(including synthetic cannabinoids) is further added as a constituent of definition 3, the 
prevalence point estimate falls to 764. This is clearly counter-intuitive, but is entirely plausible 
from a methodological perspective. By looking at confidence intervals it becomes clear that 
prevalence for definition 3 could be as high as 1,046. 
Other potential anomalies could be highlighted for Stirling and Scottish Borders. The known 
population for Stirling increased from 523 under definition 1 to 577 for definition 2. Despite an 
increase of 54, the corresponding point estimate increased only by 2 from 1,029 to 1,031. 
The opposite was observed for Scottish Borders, where a modest known population rise from 
366 under definition 1 to 391 for definition 2 resulted in a large point estimate increase from 
509 to 933 (up 83%). Only with the inclusion of confidence intervals can any estimates be 
reconciled against corresponding known populations and alternative definitions. 
The results show that even when taking confidence intervals into account apparent 
anomalies can persist. A non-statistical audience may question the results for Dumfries and 
Galloway and Stirling for instance which both provide definition 2 estimates with upper 
confidence limits that are lower than the upper limits for definition 1. Again this is entirely 
plausible from a theoretical perspective, but as the Advisory Group reiterate, introduces a 
complexity to the interpretation when comparisons are made against other definitions. 
  
Public Health Scotland 
 
32 
Final Estimated Prevalence1 by Council Area (including 95% confidence intervals) 
 PDU Definition 1 PDU Definition 2 PDU Definition 3 
  95% CI  95% CI  95% CI 
  Low High  Low High  Low High 
Aberdeen City 2,371 2,177 2,596 2,662 2,438 2,936 3,130 2,892 3,409 
Aberdeenshire2 1,185 1,050 1,360 1,308 1,148 1,555 1,600 1,366 1,878 
Angus 803 696 942 876 767 1,014 1,130 991 1,301 
Argyll and Bute 558 460 735 636 509 817 1,009 802 1,351 
City of Edinburgh3 6,012 5,604 6,486 7,552 6,940 8,280 9,049 8,299 9,926 
Clackmannanshire 610 410 786 759 637 958 1,105 938 1,339 
Dumfries and 
Galloway 1,090 938 1,332 1,109 996 1,243 1,428 1,284 1,630 
Dundee City 2,270 2,150 2,427 2,367 2,265 2,473 3,077 2,870 3,300 
East Ayrshire2,3 1,625 1,499 1,781 1,954 1,707 2,287 2,833 2,468 3,351 
East 
Dunbartonshire3 706 477 764 862 432 862 764 417 1,046 
East Lothian 919 794 1,080 1,102 917 1,321 1,383 1,160 1,679 
East Renfrewshire 804 606 1,198 1,046 804 1,592 1,536 1,169 1,986 
Falkirk2,3 1,228 1,120 1,359 1,390 1,289 1,522 2,091 1,838 2,384 
Fife 2,792 2,537 3,120 3,398 3,022 3,398 4,089 3,758 4,644 
Glasgow City 11,869 11,119 12,765 13,840 12,984 13,840 18,060 16,969 19,339 
Highland 1,354 1,243 1,526 1,603 1,414 1,603 1,909 1,721 2,150 
Inverclyde 1,489 1,296 1,697 1,655 1,451 1,655 2,022 1,776 2,352 
Midlothian 763 650 973 857 703 1,090 1,135 957 1,407 
Moray 269 207 350 367 294 367 569 486 787 
Na h-Eileanan 
Siar3 47 39 70 56 47 86 108 75 179 
North Ayrshire 1,590 1,477 1,758 1,858 1,711 2,054 3,023 2,662 3,667 
North Lanarkshire 3,619 3,251 4,118 4,038 3,748 4,390 5,840 5,288 6,524 
Orkney Islands 27 16 45 52 28 85 123 62 178 
Perth and Kinross 1,524 1,291 1,813 1,697 1,429 2,201 2,381 2,028 2,964 
Renfrewshire 2,721 2,362 3,167 3,218 2,741 3,705 4,235 3,716 5,113 
Scottish Borders 509 451 596 933 692 1,316 1,340 988 2,025 
Shetland Islands 169 124 264 190 138 360 209 154 331 
South Ayrshire 937 850 1,084 1,133 1,011 1,297 1,383 1,216 1,598 
South Lanarkshire 3,978 3,562 4,667 5,048 4,437 5,833 6,362 2,622 7,230 
Stirling 1,029 843 1,307 1,031 892 1,233 1,468 1,216 1,811 
West 
Dunbartonshire 1,140 941 1,394 1,401 1,139 1,745 1,878 1,583 2,330 
West Lothian 1,265 1,147 1,381 1,524 1,392 1,673 2,731 2,332 3,243 
          
Scotland 57,272 55,788 58,857 67,522 65,833 69,600 89,000 85,726 94,029 
1. Prevalence estimated according to published model selection criteria (10 hierarchical steps) 
2. The criteria for the hierarchical steps for this area was relaxed to allow a ‘best-fitting’ model to be chosen for 
Definition 2 
3. The criteria for the hierarchical steps for this area was relaxed to allow a ‘best-fitting’ model to be chosen for 
Definition 3  
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Appendix 3 – Publication Metadata 
 
 Metadata Indicator   Description 
Publication title Prevalence of Problem Drug Use in Scotland - 2015/16 Estimates 
A review of definitions and statistical methods 
Description This release provides a follow-up to the published estimates of the prevalence 
of problem drug use in Scotland between April 2015 and March 2016. The 
definition of problem drug use in the last report combined opioids such as 
heroin with the prescribed use of methadone or other opioid replacement 
therapies, and the illicit use of benzodiazepines. Using data collected for the 
original study, broader estimates have been constructed for Scotland based 
on the addition of substances such as cocaine (including crack cocaine), 
amphetamines (including amphetamine-type substances) and cannabis 
(including synthetic cannabinoids). 
This release presents patterns in the resulting estimates at Scotland level and 
explains limitations in the wider application of the estimation approach in a 
review of the underlying statistical methods and data sources. 
Theme Health and Social Care 
Topic Drugs and Alcohol Misuse 
Format PDF report 
Data source(s) Drug treatment services / Scottish Drug Misuse Database, SMR01 and 
SMR04, Criminal Justice Social Work Reports 
Date that data are acquired December 2017 to October 2018 
Release date 02/06/2020 
Frequency As commissioned 
Timeframe of data and 
timeliness 
The timeframe for this publication is April 2015 to March 2016. 
Continuity of data This report relates to data originally collected for the previous publication on 
2015/16 prevalence. A change has been implemented to the inclusion criteria 
in order to estimate wider definitions of problem drug use for the first time. The 
statistical methods are otherwise the same as were used by to report on 
prevalence for 2015/16, 2012/13 and 2009/10.  
Revisions statement N/A 
Revisions relevant to this 
publication 
N/A 
Concepts and definitions See main report 
Relevance and key uses of 
the statistics 
Relevant to understanding extent of problem drug use in Scotland.  Statistics 
will be used for policy making and service planning. 
Accuracy These data are estimates and users are advised to note the confidence 
intervals, which are provided to quantify a degree of uncertainty around any 
given point. Data have been provided from a number of sources, and where 
new data has been collected, validation (including assessment of 
completeness) has been undertaken through providers. Where data have 
been incorporated from routine sources, validation and data completeness 
are controlled through organisational protocols. Much of the report is 
dedicated to a review of the methods and consequences of their application 
on the robustness of estimates according to wider definitions. 
Completeness Data collected from all areas of Scotland in line with previous studies. 
Comparability Data is not comparable with the previous studies for wider definitions referred 
to in the report.  Data relating to the original definition will be the same as 
published previously and is presented again here as a comparison against the 
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wider definitions. Data may not be directly comparable with similar measures 
produced outwith Scotland, or through independent research studies. 
Accessibility It is the policy of PHS to make its web sites and products accessible 
according to published guidelines.  
Coherence and clarity The report is available as a PDF file, there are no ancillary tables or other 
visualisations. 
Value type and unit of 
measurement 
Estimated number and percentage of individuals with problem drug use 
Disclosure There is considered to be a low risk of disclosure. 
Official Statistics 
designation 
Official Statistics (Experimental) 
UK Statistics Authority 
Assessment 
Not undergoing assessment 
Last published 05/03/2019 
Next published N/A 
Date of first publication September 2001 
Help email phs.isddrugprevalence@nhs.net 
Date form completed 21/05/2020 
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Appendix 4 – Early access details 
 
Pre-Release Access 
Under terms of the "Pre-Release Access to Official Statistics (Scotland) Order 2008", PHS is 
obliged to publish information on those receiving Pre-Release Access ("Pre-Release Access" 
refers to statistics in their final form prior to publication). The standard maximum Pre-Release 
Access is five working days. Shown below are details of those receiving standard Pre-
Release Access. 
 
Standard Pre-Release Access: 
Scottish Government Health Department 
NHS Board Chief Executives 
NHS Board Communication leads 
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Appendix 5 – PHS and Official Statistics 
 
About Public Health Scotland (PHS) 
PHS is a knowledge-based and intelligence driven organisation with a critical reliance on 
data and information to enable it to be an independent voice for the public’s health, leading 
collaboratively and effectively across the Scottish public health system, accountable at local 
and national levels, and providing leadership and focus for achieving better health and 
wellbeing outcomes for the population. Our statistics comply with the Code of Practice for 
Statistics in terms of trustworthiness, high quality and public value. This also means that we 
keep data secure at all stages, through collection, processing, analysis and output 
production, and adhere to the ‘five safes’. 
 
